ArticleExpert review of anti-infective therapy2021
Drug discovery for primary amebic meningoencephalitis: from screen to identification of leads.
Article in Expert review of anti-infective therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 30 citations in OpenAlex.
- A unified digital twin framework for predicting therapeutic response to central nervous system infections by pathogenic free-living amoebae.Parasitology research · 2026Review
- Identification of Potential Therapeutic Agents for Primary Amebic Meningoencephalitis Using Text Mining and Bioinformatics Analyses.Analytical cellular pathology (Amsterdam) · 2026Article
- The potential of nanocomposites (patuletin-conjugated with gallic acid-coated zinc oxide) against free-living amoebae pathogens.International microbiology : the official journal of the Spanish Society for Microbiology · 2025Article
- Wrangling Real-World Data: Optimizing Clinical Research Through Factor Selection with LASSO Regression.International journal of environmental research and public health · 2025Article
- Next generation imidazothiazole and imidazooxazole derivatives as potential drugs against brain-eating amoebae.Parasitology research · 2024Article
- Emerging patents versus brain eating amoebae,Pharmaceutical patent analyst · 2024Review
- The increasing importance of novel deep eutectic solvents as potential effective antimicrobials and other medicinal properties.World journal of microbiology & biotechnology · 2023Review
- Nanocarrier Drug Conjugates Exhibit Potent Anti-Diseases (Basel, Switzerland) · 2023Article
- Anti-Balamuthia mandrillaris and anti-Naegleria fowleri effects of drugs conjugated with various nanostructures.Archives of microbiology · 2023Article
- Identification of novel anti-amoebic pharmacophores from kinase inhibitor chemotypes.Frontiers in microbiology · 2023Article
- Article
- Antiamoebic Properties of Laboratory and Clinically Used Drugs against Naegleria fowleri and Balamuthia mandrillarisAntibiotics (Basel, Switzerland) · 2022Article
- Antiamoebic Properties of Metabolites againstAntibiotics (Basel, Switzerland) · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.